Skip to content
OpenCapital
Get started

Vivani Medical VANI Indefinite-Lived Research and Development Assets

Indefinite-Lived Research and Development Assets at other companies

HTF
Heartflow, Inc. Common StockHTFL
$15.41M-25.5%
Photronics logo
PhotronicsPLAB
$3.9M+43.5%
Starfighters Space, Inc. logo
Starfighters Space, Inc. FJET
$244.99K—
XTI Aerospace, Inc. logo
XTI Aerospace, Inc.XTIA
$756K-37.7%
Aptera Motors Corp. logo
Aptera Motors Corp. SEV
$10.84M-13.7%
Spectral AI, Inc. logo
Spectral AI, Inc.MDAI
$598K-31.3%

Other financials

Income statement

See full
Revenue-—
Gross profit$130.0K—
Operating income-$6.8M-4.0%
Net income-$6.8M-7.6%
EPS (diluted)-$0.08+27.3%

Balance sheet

See full
Cash & equivalents$19.0M+57.7%
Total debt$18.3M-3.5%
Total equity$19.1M+64.2%
Total assets$42.4M+19.5%

Cash flow

See full
Operating cash flow-$6.2M-20.0%
CapEx$3.0K-40.0%
Free cash flow-$6.2M-19.9%

Valuation

See full
Market cap$106.93M+40.0%
Enterprise value$106.17M+19.3%

Profitability

See full
Gross margin36.3%—
Operating margin-1,004.9%—
Net margin-994.1%—
FCF margin-832.3%—

Returns & leverage

See full
Return on equity-176.4%+175pp
Debt / equity1×-0.7×
Current ratio3.2×+0.8×

Where this comes from

Reported directly by Vivani Medical in its filing.

Tagged under the XBRL concept us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment.

The official record: Vivani Medical’s 10-K, filed March 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vivani Medical's indefinite-lived research and development assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vivani Medical's indefinite-lived research and development assets?
Vivani Medical (VANI) reported indefinite-lived research and development assets of $9.26M in Q4 2025.
What is the long-term trend for Vivani Medical's indefinite-lived research and development assets?
Over 3 years (2022 to 2025), Vivani Medical's indefinite-lived research and development assets has grown at a 13.6% compound annual growth rate (CAGR), from $6.32M to $9.26M.
What does indefinite-lived research and development assets mean?
These are acquired in-process research and development assets that are not yet subject to amortization because they have not reached technical feasibility or commercialization. This balance represents the capitalized value of the company's innovation pipeline and is subject to periodic impairment testing rather than systematic amortization.